Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA
Highlight
– In the MARIPOSA exploratory, double-blind comparison, lazertinib monotherapy produced median progression-free survival (PFS) of 18.5 months versus 16.6 months for osimertinib (HR 0.98; p = 0.86), indicating comparable efficacy.
– Objective response rates (ORR) and median duration of response (DoR) were similar between arms (ORR 83% vs 85%; DoR 16.6 vs 16.8 months).
– At interim analysis, median overall survival (OS) was not reached in either arm (HR 1.00). Safety profiles were broadly comparable; lazertinib had lower rates of QT interval prolongation than osimertinib.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.